Stitched Health ads

She was IHC 2+. NCCN guideline data supported treatment, but the tumor-agnostic FDA approval covers 3+, and coverage meant trying other drugs first. Dr. Alexandra Smick on the case, and Dr. Dana Chase on documenting the appeal without pretending the patient meets the label.

Two mistakes when your patient wasn’t in the randomized trial: assuming she can’t have the treatment, or assuming she’ll get the trial’s result. Dr. Dana Chase and Dr. Alexandra Smick on trial exclusion versus clinical suitability.

Treatment decisions depend on folate receptor alpha, HER2 and PD-L1 status, and you don’t want to wait on a result once she needs to start therapy. Dr. Dana Chase on two habits that get therapy to the patient faster: test early, and document the oncologic history before you need it.

Weekly paclitaxel with bevacizumab, or PLD with bevacizumab: easy to order, familiar toxicity, no need to look anything up. Dr. Dana Chase on why that familiarity is really a form of safety, and the deliberate pause before the next treatment order that asks whether another option fits this patient.

1 in 5 women have migraine. Per the WHO Global Burden of Disease study, it is the leading cause of years lived with disability in women of reproductive age. Dr. Amaal Starling on why a three-question annual screener and CGRP-targeted options change what’s feasible in a routine visit.

1 in 5 women have migraine. Fewer than half have ever raised it with a doctor. Dr. Amaal Starling on why screening (not waiting to be asked) is the first move, and what changes once a woman is actually diagnosed.